Optimum TV launches amid green shoots from the biotech markets
The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work.
Heidelberg grabs orphan designation
Heidelberg Pharma AG on Monday published its financial results and Annual Report for fiscal year 2023 (1 December 2022 – 30 November 2023) and its outlook for 2024.
Highlights included first efficacy data from the clinical trial of HDP-101 in multiple myeloma, expansion of the ADC technology platform to include further payloads and a new management board team. The Company followed this on Wednesday with the announcement that HDP-101 had been granted orphan designation for the treatment of multiple myeloma by the FDA.
STORM Therapeutics to present data on first-in-class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024
STORM Therapeutics. Ltd announced on Tuesday that it will present late breaking data on its METTL1 inhibitors at the American Association for Cancer Research in San Diego, California, held 5-10 April 2024.
Alexandra Sapetschnig, group leader at STORM, will announce the data from the clinical stage biotech, which discovers and develops novel small molecule therapies targeting RNA modifying enzymes for other diseases.
Curve CSO’s research published in Journal of the American Chemical Society highlighting potential of HIF Inhibition as a therapeutic approach for cancers
Curve Therapeutics, a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, on Tuesday announced the publication of an article in the Journal of the American Chemical Society (JACS).
Curve’s Chief Scientific Officer, Professor Ali Tavassoli, co-authored the article and leads the academic group at the University of Southampton where the work was undertaken. The paper is the first report of a dual HIF-1 and HIF-2 inhibitor which functions by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β and can be viewed here.
Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium
Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, on Tuesday announced that it has joined the Critical Path Institute’s, Critical Path for Alzheimer’s Disease (CPAD) Consortium.
With its highly experienced leadership team and world class Scientific Advisory Board of leading experts in neurodegenerative diseases, Asceneuron is well positioned to contribute to the consortium.
Vicore presents late-breaking phase 2a data of buloxibutid in IPF
Vicore Pharma Holding AB, a company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), on Thursday announced multiple presentations at the 2024 American Thoracic Society (ATS) International Conference.
These included an oral late-breaking presentation of the final phase 2a AIR data of buloxibutid (C21) in patients suffering from idiopathic pulmonary fibrosis (IPF).
